

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RUI KANG PHARMACEUTICAL GROUP INVESTMENTS LIMITED

銳康藥業集團投資有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

**RESIGNATION OF NON-EXECUTIVE DIRECTOR
AND
CHANGE OF COMPANY SECRETARY**

The Board of the Company announces that, with effect from 9 October 2017:

- (1) Mr. Gao has tendered his resignation as a non-executive Director; and
- (2) Mr. Fung has resigned as the Company Secretary and Ms. Wong was appointed as the Company Secretary.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”, and each, a “**Director**”) of Rui Kang Pharmaceutical Group Investments Limited (the “**Company**”) announces that Mr. Gao Yongping (“**Mr. Gao**”) has tendered his resignation as a non-executive Director with effect from 9 October 2017 due to his other business commitments which require more of his dedication. Mr. Gao has confirmed that he has no disagreement with the Board and there are no matters with respect to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to express its sincere appreciation to Mr. Gao for his invaluable contributions to the Company during the tenure of his office.

CHANGE OF COMPANY SECRETARY

The Board also announces that with effect from 9 October 2017, Mr. Fung Wing Sang (“**Mr. Fung**”) has resigned as the company secretary of the Company (the “**Company Secretary**”). Mr. Fung confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board is pleased to announce the appointment of Ms. Wong Miu Shun (“**Ms. Wong**”) as the Company Secretary with effect from 9 October 2017. Ms. Wong graduated from City University of Hong Kong with Bachelor of Business Administration in Accountancy and is a member of the Hong Kong Institute of Certified Public Accountants.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Fung for his invaluable contribution and services during his tenure of office and welcome Ms. Wong to her new appointment.

By order of the Board
Rui Kang Pharmaceutical Group Investments Limited
LIU Xiaolin
Chairman and Executive Director

Hong Kong, 9 October 2017

As at the date of this announcement, the executive Directors are Mr. LIU Xiaolin (Chairman), Mr. LEUNG Pak Hou Anson, and Mr. WANG Zheng; the non-executive Director is Mr. HUANG Song; and the independent non-executive Directors are Mr. HO Fung Shan Bob, Mr. LEUNG Ka Fai and Mr. YAN Guoxiang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.ruikang.com.hk.